Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
US IPO Weekly Recap: Two deals flounder while one soars
Analyst IPO Market Commentary
Three IPOs raised $495 million this week, led by
), which popped 53% on its first day. The other two IPOs,
), priced below the range and closed the week down 1% and 6%, respectively. Forterra’s 8% drop on its first day was the eighth worst first day of 2016.
October has seen 13 IPOs, which makes it the third busiest month for IPOs in 2016, but to get done, eight priced below the range, and eight companies closed Friday below their IPO price. Just 39% of October IPOs are trading above issue, and the average October IPO is up just 7%, compared to the average 2016 IPO which is up 29%.
IPO Pricings Week of October 17th, 2016
Leading drainage and potable water pipe company in the US and Eastern Canada.
iRhythm Technologies (IRTC)
Provides a device and analysis for detecting cardiac arrhythmias.
CRISPR Therapeutics (CRSP)
Preclinical biotech developing therapies based on CRISPR/Cas9 gene editing.
) - Since it was acquired by Lone Star from HeidelbergCement in 2015, Forterra has focused its business on drainage and potable water infrastructure and acquired six companies (totaling $1.2 billion), which have helped it increase its product breadth and geographic reach. While the acquisitions have helped it become a leader in the $10+ billion water infrastructure market with 30-50% share, Forterra faces risks due to the cyclicality of the industry and its high, floating rate debt load of 4.7x PF LTM EBITDA. Investors required a deeper discount to complete the deal, which priced 10% below its midpoint and fell 8% on its debut.
) - This venture-backed medical device maker attracted strong investor demand, pricing 21% above its midpoint and popping 53% on its debut. The company has an attractive growth profile, with revenue growth accelerating to 79% in the 1H16 from 66% in 2015. Its device appears to provide superior diagnosis abilities for cardiac arrhythmias relative to competitors, which should continue to drive its growth in its $1.4 billion target market.
) - This gene-editing biotech was the third of its kind this year, joining peers Editas Medicine and Intellia Therapeutics in the public market. While the CRISPR/Cas9 technology has massive potential to treat thousands of diseases, all three companies are still very early stage, with human testing yet to begin. Editas and Intellia were both high-flyers earlier this year, but they now trade below their respective IPO prices, which, along with uncertainty in the ongoing IP interference proceedings, may have led to decreased interest for CRISPR.
IPO Pipeline Update
Eight companies launched their deals this week: Golf equipment and apparel maker
), Chinese data center services provider
), endocrine disorders biotech
), medical-use cannabis facilities REIT
Innovative Industrial Properties
), cloud-based financial reporting software provider
), Wi-Fi chip designer
), rare disorder-focused biotech
) and chemical rodent control company
One company submitted a filing this week: micro-cap biotech
Find out why institutional investors rely on Renaissance Capital's
for these IPOs.
Follow us on Twitter (
) for IPO news as it happens and
register for our updates
on the IPO market.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance IPO Index gained 2.1% this past week compared to the S&P's +0.4%, though the IPO Index's year-to-date gain of 0.5% still trails the S&P's 5%. Renaissance Capital's
(NYSE: IPO) tracks the index, and
top ETF holdings
include Alibaba (
) and Citizens Financial Group (
). The Renaissance International IPO Index is down 2% year-to-date, while ACWX is up 4%. Renaissance Capital’s International
(NYSE: IPOS) tracks the index, and
top ETF holdings
include Recruit Holdings and Cheil Industries.
To find out if this is the best ETF for you, visit our
IPO Investing page
Keywords / Tickers:
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds.
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges.
The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE or Nasdaq.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.